Boehringer Ingelheim and Zai Lab collaborate on DLL3-targeting T-cell engager and ADC combination in SCLC and other neuroendocrine carcinomas: Ingelheim, Germany Friday, April 17, ...
Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune ...
If you’re seeking postcard-perfect views of Table Mountain, world-class watersports, and a relaxed coastal vibe, Blaauwberg ...
BioNTech partners with Boehringer Ingelheim on lung cancer combo therapy, advances malaria vaccine, and plans capital raise to fund 15 Phase 3 oncology trials by 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results